Oligometastatic Malignant Solid Neoplasm clinical trials at University of California Health
1 research study open to eligible people
Total RadIoTherapy of Oligometastatic caNcerS
open to eligible people ages 18 years and up
This is a Phase III non-blinded randomized study evaluating patients with oligometastatic cancers (up to 10 metastases). Subjects are randomized 1:1 to stereotactic ablative radiotherapy (SABR) plus standard of care therapies versus SABR alone. The investigators will measure progression-free survival at 2 years based on the hypothesis that subjects treated with SABR plus standard of care will not experience disease progression for a longer period of time than subjects treated with standard of care alone. The investigators will also measure overall survival and safety of SABR, as well as biomarkers that may help predict, in the future, who will benefit from the SABR treatment.
at UCSD
Last updated: